News

The province of Manitoba has listed RADICAVA Oral Suspension on the Manitoba Pharmacare Program (Exceptional Drug Status) as a treatment for ALS. With this announcement, all provinces and territories across Canada – as well as Veterans Affairs Canada and Indigenous…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

A letter from Tammy Moore, ALS Canada’s Chief Executive Officer Let me start by saying thank you. Thank you for standing beside us throughout the year, driven by our shared vision: a future without ALS. Today, I want to…

Double your impact this GivingTuesday When it comes to fundraising for ALS, next Tuesday (November 28) is the single most important day of the year, and to help us celebrate the day, we have an exciting announcement. Does this sound intriguing?…

On World Science Day, the latest ALS Canada-Brain Canada research awards, with support from Fondation Vincent Bourque, highlight the importance of funding early-career researchers and clinicians   Toronto — In recognition of World Science Day, together with Brain Canada,…

ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the October 2023 Research Update, you’ll learn about advances in understanding the presymptomatic stage…

That’s a wrap! Our September events have come to an end at ALS Canada, and we can’t help but look back at how the community came out to ride and pull to end ALS. Both the ALS Canada Pull…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…